Antidepressants Global Market Report 2024

The antidepressants market size has grown steadily in recent years. It will grow from $16.6 billion in 2023 to $17.32 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The historical period's growth can be ascribed to a rise in the prevalence of mental health disorders, heightened awareness coupled with reduced stigma, advancements in diagnostic methods, an expansion of available treatment options, and government initiatives and policies focused on mental health.

The antidepressants market size is expected to see steady growth in the next few years. It will grow to $19.88 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The forecasted growth in the upcoming period can be linked to an increase in awareness and advocacy for mental health, the global influence of stress and lifestyle changes, the integration of mental health services, ongoing research and development in psychiatry, and the utilization of telemedicine and remote mental health services. Noteworthy trends anticipated in the forecast period encompass regulatory adjustments, intensified market competition, the expansion of the generic market, a heightened focus on side effect profiles, and the emergence of new markets.

The global surge in mental health disorders is a pivotal factor contributing to the expansion of the antidepressant drug industry, with a considerable number of individuals relying on these medications to address conditions such as depression, anxiety disorders, and various mental illnesses. Antidepressant drugs find application in treating a spectrum of disorders, including OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. The prevalence of depression globally ranges from 2% to 6%, with the elderly facing a higher risk compared to other age groups. According to the World Health Organization (WHO), approximately 280 million people worldwide suffered from depression in 2023, highlighting the escalating cases of mental health disorders as a driving force for the antidepressant market.

The escalating incidence of mental illnesses is anticipated to foster the demand for the antidepressants market in the future. Mental illnesses, characterized by disruptions in thinking, feeling, behavior, or beliefs, pose challenges in social, occupational, or familial activities. Antidepressants, a category of medications designed to address various mental health conditions, including depression, anxiety, and mood disorders, function by elevating the levels of specific chemicals in the brain responsible for mood and emotion regulation. A report from a US-based government agency in June 2022 indicated that 970 million individuals globally had a mental disorder in 2019. Furthermore, the National Alliance on Mental Illness reported that 21% of US adults, equivalent to 52.9 million people, faced mental illness in 2020, underscoring the role of increasing mental illnesses in propelling the antidepressants market.

The growth of the antidepressant market faces hindrances due to the side effects associated with antidepressant drugs. Medications such as Lexapro and Celexa, used to treat depression and anxiety, may lead to common side effects such as nausea, insomnia, sweating, dry mouth, and drowsiness. More severe side effects, including excessive bleeding, seizures, and vision problems, pose additional risks. These side effects are anticipated to curtail the expansion of the antidepressant market.

A noteworthy trend in the antidepressant market is the treatment of resistant depression, with ketamine emerging as a novel therapeutic approach. Ketamine, initially used for anesthesia during surgery, stimulates glutamate development, prompting the brain to form new neural connections. This enhances the brain's adaptability and capacity to develop new pathways, aiding individuals in fostering more positive thoughts and behaviors. The Food and Drug Administration (FDA) approved esketamine, a new ketamine depression drug, in a nasal spray form for patients who have unsuccessfully tried two antidepressants before.

Major companies in the antidepressant market are strategically focusing on introducing new drugs to maximize revenue. For example, Biogen Inc and Sage Therapeutics, Inc. launched ZURZUVAE (zuranolone) in August 2023, an oral treatment for postpartum depression (PPD), addressing the underdiagnosed and undertreated condition. ZURZUVAE (zuranolone) is the first FDA-approved medication specifically designed for PPD.

In October 2021, ShineCo., Inc. announced its entry into a framework agreement to acquire a majority stake in Beijing Wonner Biotech Co., Ltd. for $30 million. This acquisition aims to collaborate on the development of SNG, a rapid-acting natural innovative medicine for antidepressant purposes. Beijing Winner is a Chinese biotechnology company specializing in the research and development of natural medicines and related products.

Major companies operating in the antidepressants market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Fresenius Kabi AG, Abbott Laboratories, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Boehringer Ingelheim GmbH, H. Lundbeck AS, Teva Pharmaceutical Industries Ltd., Akeda Pharmaceutical Co., Otsuka Pharmaceutical Co., Mylan N.V, Sun Pharmaceuticals Pvt. Ltd., Servier Laboratories, Sumitomo Dainippon Pharma Co., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Allergan PLC, Alkermes PLC, Egis Pharmaceuticals PLC, Forest Laboratories Inc. North America was the largest region in the antidepressants market in 2023. Middle East is expected to be the largest growing region in the global antidepressants market during the forecast period. The regions covered in the antidepressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary categories of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs, a widely used medication type, are employed not only for treating depression but also for addressing certain other mental health conditions. The diverse range of drug classes encompasses monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants, all of which find application in treating major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder.

The antidepressants market research report is one of a series of new reports that provides antidepressants market statistics, including antidepressants industry global market size, regional shares, competitors with an antidepressants market share, detailed antidepressants market segments, market trends, and opportunities, and any further data you may need to thrive in the antidepressants industry. This antidepressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The countries covered in the antidepressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antidepressants market consists of sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.